GlassScriptPhysician profile
Ezara Gutierrez
NPI 1942738240
$1,143.64
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.79 · 2021: $41.03 · 2022: $289 · 2023: $472 · 2024: $128 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $512.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Galderma Laboratories, L.P. | $186.68 | 2022-2025 | |
| Abbvie INC. | $133.93 | 2023 | |
| Novo Nordisk INC | $110.97 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Acella Pharmaceuticals, LLC | $37.96 | 2023-2024 | NP Thyroid 60 |
| Ibsa Pharma INC. | $23.41 | 2025 | Licart, Flector, Tirosint |
| Endo Pharmaceuticals INC. | $20.57 | 2020 | |
| Pfizer INC. | $17.83 | 2024 | |
| Halozyme INC | $17.03 | 2023 | |
| Acerus Pharmaceuticals Corporation | $16.63 | 2021 | |
| Glaxosmithkline, LLC. | $16.12 | 2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.85 | 2024 | Xifaxan |
| Amgen INC. | $12.44 | 2021 | |
| Therapeuticsmd, INC. | $12.22 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezara Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.